Clinical Trials Logo

Left Ventricular Assist Device clinical trials

View clinical trials related to Left Ventricular Assist Device.

Filter by:

NCT ID: NCT03217331 Completed - Right Heart Failure Clinical Trials

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices

Start date: March 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/IIa, single centre, non-randomised open-label uncontrolled study to assess safety, effect and PK of oral CRD-102 in patients with RHF associated with the presence of an LVAD.

NCT ID: NCT03143569 Completed - Clinical trials for Gastro Intestinal Bleeding

Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

VAD-ANTIX
Start date: May 20, 2017
Phase: N/A
Study type: Interventional

This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD]. One method tests for how long it takes the patient's blood to clot and uses that to determine if they are on the right dose of heparin. The other method uses a more direct measure of how much heparin is in the blood. The hypothesis is that the method that more directly measures how much heparin is in the patient's blood will provide better medical results for the patient's care after they have the heart pump implant. To that end, the investigators are conducting this feasibility trial to establish the logistics associated with the implementation of these heparin monitoring approaches.

NCT ID: NCT03091998 Withdrawn - Heart Failure Clinical Trials

Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support

CD-NP/LVAD
Start date: September 30, 2017
Phase: Phase 1
Study type: Interventional

The worldwide use of left ventricular assist devices (LVAD), which is mechanical device to improve hemodynamic function, has improved the outcomes of severe heart failure (HF) patients leading to the continued annual increase in the number of LVAD implantations. However LVAD support still results in major complications such as renal failure or gastrointestinal bleeding. The investigators hypothesize that such major complications may be due to endothelial dysfunction induced by the lack of pulsatility, which may be improved by an innovative designer natriuretic peptide, CD-NP. They have demonstrated its favorable actions in animal models as well as humans, and tested its safety in LVAD patients. They hypothesize that CD-NP will have renal and endothelial protective actions through its receptor GC-A and GC-B. Thus, the investigators will test their hypothesis with a highly translational approach to examine CD-NP's role in endothelial and renal protection. The aim is to determine safety and tolerability together with cGMP activating, neurohumoral modulating and renovascular protective properties of chronic subcutaneous delivery of CD-NP compared to placebo in stable LVAD patients for 3 days.

NCT ID: NCT01642927 Withdrawn - Heart Failure Clinical Trials

Pulse Wave Analysis in Advanced Heart Failure

PWA-HF
Start date: February 2012
Phase:
Study type: Observational

A comparison of pulse wave characteristics, as measured by peripheral tonometry, in pre and post Left Ventricular Assist Device (LVAD) patients.

NCT ID: NCT01485666 Completed - Clinical trials for Left Ventricular Assist Device

Thoratec's Reduce Driveline Trauma Through Stabilization and Exit Site Management Study

RESIST
Start date: May 2012
Phase:
Study type: Observational

The purpose of this study is to evaluate the feasibility of a Percutaneous Lead Management Kit for HeartMate II driveline stabilization and exit site management.

NCT ID: NCT01477528 Completed - Anticoagulation Clinical Trials

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

TRACE
Start date: November 2011
Phase:
Study type: Observational

The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events associated with these regimes.